Pancreatobiliary Carcinoma — Trials

Pancreatobiliary Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

2,128 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 698
Recruiting: 403
Ph III recruiting: 36
Growth YoY: +22%
Industry share: 30%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (303)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07573215	Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma	approved for marketing	—	—	Revolution Medicines, Inc.INDUSTRY	2	Sep 1, 2026	clinicaltrials
NCT04507503	Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements	approved for marketing	—	—	Taiho Oncology, Inc.INDUSTRY	1	Mar 10, 2026